Company intelligence / Profile preview
Aurospharma
San Diego, California, USAaurospharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Auros Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare metabolic diseases, particularly Urea Cycle Disorders (UCD). The company's lead program, ARS-101, is a next-generation nitrogen scavenger designed to provide a more effective and patient-friendly alternative to existing treatments for hyperammonemia. By leveraging advanced drug delivery and formulation technologies, Auros Pharma aims to address the significant unmet needs of patients living with life-threatening orphan conditions. The company is privately held and based in San Diego, California.
- Therapeutic areas
- Metabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Aurospharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurospharma.